Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $389,100.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Thomas Gad also recently made the following trade(s):

• On Friday, September 13th, Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $13.47, for a total value of $875,550.00.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $14.31 on Wednesday. The company’s fifty day simple moving average is $12.70 and its 200-day simple moving average is $13.52. Y-mAbs Therapeutics, Inc. has a 52 week low of $4.69 and a 52 week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The company had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same quarter in the prior year, the company posted ($0.14) earnings per share. As a group, research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds have recently modified their holdings of the stock. Campbell & CO Investment Adviser LLC acquired a new stake in Y-mAbs Therapeutics in the fourth quarter valued at approximately $562,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Y-mAbs Therapeutics by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock worth $136,000 after purchasing an additional 3,340 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after purchasing an additional 1,657 shares during the period. Finally, Caxton Associates LP acquired a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $306,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on YMAB. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Truist Financial assumed coverage on Y-mAbs Therapeutics in a report on Friday, June 28th. They set a “buy” rating and a $21.00 price objective for the company. Finally, BMO Capital Markets reduced their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.